!!Research output per year
!!Research output per year
Vingerafdruk
Verdiep u in de onderzoeksgebieden waarop Anja Seckinger actief is. Deze onderwerplabels komen uit het werk van deze persoon. Samen vormen ze een unieke vingerafdruk.
- 1 Soortgelijke profielen
Samenwerkingen en hoofdonderzoeksgebieden uit de afgelopen vijf jaar
Recente externe samenwerking op landen-/regioniveau. Duik in de details door op de stippen te klikken of
-
Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025
Choon-Quinones, M., Obeng, G. D., Asiedu-Ayeh, B., Kawuo, S., Tukur, A. M., Mohammed, I., Obeng, A. P., Harousseau, J.-L., Seckinger, A., Hose, D., Sarkodie, E., Imre, A. & Marcell, C., jun. 2026, In: European Journal of Haematology. 116, 6, blz. 724-732 9 blz.Onderzoeksoutput: Scientific review › peer review
Open AccessBestand10 Downloads (Pure) -
Prognostic Impact of the Hevylite Assay in Patients With IgG or IgA Multiple Myeloma Treated Within the GMMG-MM5 Trial
German‐Speaking Myeloma Multicenter Group (GMMG) HD5 Investigators, Richardson, T., Mai, E., Menis, E., Benner, A., Tichy, D., Miah, K., Hänel, M., Besemer, B., Boquoi, A., Blau, I. W., Michel, C. S., Lindemann, H. W., Janjetovic, S., Brossart, P., Bernhard, H., Reimer, P., Salwender, H., Hose, D. & Seckinger, A. & 3 anderen, , mrt. 2026, In: European Journal of Haematology. 116, 3, blz. 226-234 9 blz.Onderzoeksoutput: Article › peer review
Open AccessBestand1 Downloads (Pure) -
Correction to: Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma (Journal of Hematology & Oncology, (2024), 17, 1, (128), 10.1186/s13045-024-01636-4)
Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., Khassawna, T. E., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M. & Kampschulte, M. & 6 anderen, , 24 jan. 2025, In: Journal of Hematology & Oncology. 18, 1, 1 blz., 11.Onderzoeksoutput: Comment/debate
Open Access -
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group, Shi, Q., Paiva, B., Pederson, L. D., Dimier, N., Talpes, E., Prior, T. J., Orfao, A., Moreau, P., Sonneveld, P., Kumar, S. K., Dixon, J. G., Patel, R., Bartlett, B. J., Schecter, J., McCarthy, P., Hose, D., Seckinger, A., Mattia, D. & Goldschmidt, H. & 6 anderen, , 10 apr. 2025, In: Journal of Clinical Oncology. 43, 11, blz. 1289-1301 13 blz.Onderzoeksoutput: Article › peer review
38 Citaten (Scopus) -
Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
Hose, D., Ray, S., Rößler, S., Thormann, U., Schnettler, R., de Veirman, K., El Khassawna, T., Heiss, C., Hild, A., Zahner, D., Alagboso, F., Henss, A., Beck, S., Emde-Rajaratnam, M., Burhenne, J., Bamberger, J., Menu, E., de Bruyne, E., Gelinsky, M. & Kampschulte, M. & 6 anderen, , 18 dec. 2024, In: Journal of Hematology & Oncology. 17, 1, 20 blz., 128.Onderzoeksoutput: Article › peer review
Open AccessBestand3 Citaten (Scopus)28 Downloads (Pure)